

Detection and Antibiotic Susceptibility of *Mycoplasma bovis* and Other Respiratory Disease Pathogens from Pneumonic Lung Samples in a Calf Rearing Unit

Umit OZDEMİR¹, M Ali TURKYILMAZ¹ and Robin AJ NICHOLAS^{2*}

¹Veterinary Control and Research Institute, 34890 Pendik, Istanbul, Turkey

²The Oaks, Nutshell Lane, Farnham Surrey, GU9 0HG, UK

Article Info

*Corresponding author:

Robin AJ Nicholas

The Oaks
Nutshell Lane
Farnham Surrey, GU9 0HG
UK
E-mail: robin.a.j.nicholas@gmail.com

Received: December 17, 2018

Accepted: April 1, 2019

Published: April 8, 2019

Citation: Ozdemir U, Turkyilmaz MA, Nicholas AJ. Detection and Antibiotic Susceptibility of *Mycoplasma bovis* and Other Respiratory Disease Pathogens from Pneumonic Lung Samples in a Calf Rearing Unit. *Madridge J Vet Med Res.* 2019; 1(1): 8-12.
doi: 10.18689/mjvmr-1000102

Copyright: © 2019 The Author(s). This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published by Madridge Publishers

Abstract

Mycoplasma bovis, a serious cause of bovine respiratory disease often associated with other bacteria and viruses, is prevalent worldwide including Turkey. It is difficult to control because antibiotics are becoming increasingly ineffective and commercial vaccines are not available. The aims of this study were to detect infective agents causing respiratory disease in a calf rearing unit in Turkey, to determine antibiotic susceptibilities of the strains isolated and to carry out molecular typing. In diseased lungs from calves dying of pneumonia we found *M.bovis* to be present in all samples of acute and chronic diseased tissue. *Mannheimia haemolytica* was detected mostly in chronic tissue (39%) while the reverse was true for *Pasteurella multocida* with most isolations from acute tissue (25%). High minimum inhibitory concentrations (MIC) were seen for most antibiotics against *M.bovis*: tylosin, tilmicosin, erythromycin, chloramphenicol, oxytetracycline and ciprofloxacin with MIC50s of >32 µg/ml, intermediate-sensitivity to florfenicol, spectinomycin, danofloxacin, enrofloxacin and marbofloxacin with MIC50 of 8 µg/ml, and susceptible to lincomycin, clindamycin and tulathromycin with MIC50 of 1, 0.25, 0.25 µg/ml respectively. While all tested isolates of both *M.haemolytica* and *P. multocida* were resistant to gentamicin, *P. multocida* isolates showed resistance rates of 100% to erythromycin and tylosin, 88% to trimethoprim-sulphamethoxazol, 75% to tetracycline and tilmicosin, 50% to tulathromycin and enrofloxacin. The resistance rates of *M.haemolytica* isolates were 90% to erythromycin, 75% to tylosin, 64% to tetracycline, 55% to trimethoprim-sulphamethoxazol, 36% to tilmicosin, 18% to enrofloxacin, 9% to marbofloxacin, florfenicol, ampicillin and penicillin. Finally, *M. bovis* could be divided into two distinct genetic clusters by molecular typing tests.

Keywords: *Mycoplasma bovis*; *Mannheimia haemolytica*; *Pasteurella multocida*; Calf; Pneumonia; Antibiotic susceptibility.

Introduction

Diseases of the bovine respiratory system are causes of major economical losses in cattle farms worldwide. Bovine pneumonic pasteurellosis, also known as bovine respiratory disease (BRD), bovine enzootic bronchopneumonia or respiratory disease complex of cattle, is a multifactorial disorder caused by a combination of one or more viruses, bacteria and mycoplasmas. It is estimated that BRD is one of the most important diseases in the cattle industry with a global mortality and morbidity that are estimated to exceed 1% and 10% of young cattle respectively [1].

Mycoplasma bovis is the most important and most pathogenic bovine mycoplasma worldwide. It was reported that *M.bovis* is responsible for 25-33% of all calf pneumonias in Europe [2] and the most serious pathogen in the feedlots of North America [3]. In 2006 the first reports from western Turkey described the isolation of *M.bovis* from just under a third of lungs of calves affected by pneumonia in a calf rearing unit [4]. Later studies confirmed the presence of *M. bovis* throughout Turkey [5].

M. bovis is frequently associated with other pathogenic microorganisms such as bovine respiratory syncytial virus (BRSV), parainfluenza 3 virus (PI-3), bovine adenoviruses, bovine viral diarrhoea virus (BVDV), bovine herpesvirus 1 (BoHV1), *Pasteurella multocida*, *Mannheimia haemolytica*, *Arcanobacterium pyogenes*, *Histophilus somni*, *Mycoplasma dispar*, *Mycoplasma canis* and *Ureaplasma diversum*. These infective agents usually exacerbate disease initiated by *M.bovis*[2].

Control of bovine mycoplasmosis is hampered by the increasing resistance of *M. bovis* to antibiotics like the tetracyclines and macrolides routinely used for respiratory disease [6,7]. Furthermore no commercial vaccines are presently available. An inactivated vaccine for calf pneumonia caused by *M.bovis* reduced clinical disease, weight loss, lung lesions and spread to internal organs under experimental conditions [8]. Some success was seen in the UK with an autogenous vaccine which reduced mortality and treatment costs on some calf units [9]. However *M.bovis* has been shown to be genetically diverse by molecular typing tests [10,11] so it is not certain that a vaccine will protect against all strains.

The aims of this study were to detect infective agents causing respiratory disease in a calf rearing unit in Turkey in 2015, to determine antibiotic susceptibilities of the strains isolated and to carry out molecular typing of *M.bovis* strains with the ultimate aim of producing an inactivated autogenous vaccine.

Material and Methods

All diagnostic work was carried out at the Veterinary Control and Research Institute Pendik in between March and September in 2015.

Samples

Lungs of 20 calves with acute pneumonia and lungs of 23 calves with chronic pneumonia based on histopathological findings were subjected to bacterial examination. All samples belonged to calves in a calf rearing unit, originating from multiple farms in Turkey.

Isolation and identification

The lung samples were inoculated onto chocolate agar for the isolation of *H.somni* [12] and onto 5% sheep blood agar plates (Oxoid) for the isolation of *P.multocida* and *M. haemolytica* [1]. Suspect colonies were further purified and identified using an automated Vitek 2 System.

Mycoplasma isolation and identification was attempted from post mortem samples. Samples for culture included material from lung areas at the interface between healthy

tissue and lesions [13]. Isolates were grown in liquid and solid Eaton's mycoplasma media. Semi-solid agar plates were inoculated with a loop full of the broth from cultures showing mycoplasma growth. *M.bovis* was identified by growth inhibition test using specific rabbit antiserum [14] and confirmed by PCR/denaturing gradient gel electrophoresis (DGGE) [10].

Viral antigen detection

The Bio-X Pulmotest tetra ELISA kit was used for PI, BRSV, BoHV1 and BVDV antigens in lung tissue. Detection of adenovirus 3 antigen was performed using Bio-X Adenovirus 3 ELISA kit.

Typing by pulse field gel electrophoresis (PFGE)

The PFGE was performed for genotyping of *M.bovis* isolates as described previously [15]. Briefly 10 ml of stationary-phase cultures were harvested by centrifugation, washed and resuspended in buffer. Agarose plugs were incubated in lysis buffer then washed. Slices were cut aseptically from the plugs and equilibrated in restriction buffer for 1 h. Restriction digestion was performed with SmaI according to the manufacturer's instructions. The fragments were resolved on 1% pulsed-field-agarose gels with a CHEF-DRIII system at 6 V/cm. Gels were stained with ethidium bromide and photographed under UV light. A lambda ladder PFGE marker was used for fragment size determination.

Antimicrobial susceptibility testing for conventional bacteria

Susceptibility testing by the disk diffusion method was performed by means of the direct inoculation method on Mueller Hinton II agar [16]. The antibiotics used are listed in table 1.

Minimum inhibitory concentration test (MIC) for *M. bovis*

The MIC test was performed by microdilution method [6]. The antibiotics used are listed in table 2. While no official criterion for antimicrobial susceptibility testing exists for animal mycoplasmas as yet we used the guidelines of Ayling et al. [6] for human mycoplasmas. Strains with MIC values of <2 were considered susceptible; >2 to 8 intermediate susceptible and >8 as resistant.

Results

Bacterial detection

Twenty acute pneumonic lung samples and 23 chronic pneumonic lung samples from calves in a calf rearing unit were examined for the presence of *M. bovis* and other respiratory disease pathogens. While *M.bovis* was isolated from all samples, the isolation rate of *M. haemolytica* was 10% (2 cases) and *P. multocida* was 25% (5 cases) in the acute pneumonic samples. In the test for BVDV antigen, 18% (2 cases) of the acute pneumonic samples were found positive. The isolation rates in the chronic pneumonic samples were 39% (9 cases) for *M.haemolytica* and 13% (3 cases) for *P. multocida*. BVDV antigen was detected in 18% (2 cases) of chronic pneumonic samples. *H. somni* was not isolated from any of the samples.

Antimicrobial susceptibility testing

While all isolates of both *M.haemolytica* and *P.multocida* were resistant to gentamicin, *P.multocida* isolates showed resistance rates of 100% to erythromycin and tylosin, 88% to trimethoprim-sulphamethoxazol, 75% to tetracycline and tilmicosin, and 50% to tulathromycin and enrofloxacin. The

resistance rates of *M.haemolytica* isolates were 90% to erythromycin, 73% to tylosin, 64% to tetracycline, 55% to trimethoprim-sulphamethoxazol, 36% to tilmicosin, 18% to enrofloxacin, 9% to marbofloxacin, florfenicol, ampicillin and penicillin. Higher antibiotic resistance was observed in the isolates from acute cases than in those from chronic cases (Table 1).

Table 1. Antimicrobial susceptibility testing of *M. haemolytica* and *P. multocida* strains.

No	Strains	AMP			AMX			PEN			GEN			TET			ENR			ERY			SXT			TUL			TIL			TYL			MBF			FLO			CTF		
		R	I	S	R	I	S	R	I	S	R	I	S	R	I	S	R	I	S	R	I	S	R	I	S	R	I	S	R	I	S	R	I	S	R	I	S	R	I	S			
1	A*13/08 <i>M. haemolytica</i>			x			x	x			*		x			x	x		x	x		x	x		x	x		x	x		x	x		x	x		*	*	*				
2	A14/08 <i>P. multocida</i>			x			x			x	x		x			x	x		x	x		x	x		x	x		x	x		*	*	*		x	*	*	*					
3	A15/08 <i>P. multocida</i>			x			x			x	x		x			x	x		x	x		x	x		x	x		x	x		*	*	*		x	*	*	*					
4	A16/08 <i>P. multocida</i>			x			x			x	x		x			x	x		x	x		x	x		x	x		x	x		*	*	*		x	*	*	*					
5	A17/08 <i>P. multocida</i>			x			x			x	x		x			x	x		x	x		x	x		x	x		x	x		*	*	*		x	*	*	*					
6	A18/08 <i>M. haemolytica</i>			x			x			x	x		x			x	x		x	x		x	x		x	x		x	x		*	*	*		x	*	*	*					
	A18/08 <i>P. multocida</i>			x			x			x	x		x			x	x		x	x		x	x		x	x		x	x		*	*	*		x	*	*	*					
7	C**1/08 <i>M. haemolytica</i>			x			x			x	x		x			*	*	*	x			x	x		x	x		x	x		*	*	*		x	*	*	*					
8	C2/08 <i>M. haemolytica</i>			x			x			x	x		x			x	*	*	*	x			x	x		x	x		x	x		*	*	*		x	*	*	*				
9	C8/08 <i>M. haemolytica</i>			x			x			x	x		x			x	*	*	*	x			x	x		x	x		x	x		*	*	*		x	*	*	*				
10	C11/08 <i>M. haemolytica</i>			x			x			x	x		x			*	*	*	x			x	x		x	x		x	x		*	*	*		x	*	*	*					
11	C13/08 <i>P. multocida</i>			x			x			x	x		x			x	*	*	*	x			x	x		x	x		x	x		*	*	*		x	*	*	*				
12	C14/08 <i>M. haemolytica</i>			x			x			x	x		x			x	*	*	*	x			x	x		x	x		x	x		*	*	*		x	*	*	*				
13	C17/08 <i>M. haemolytica</i>			x			x			x	x		x			x	*	*	*	x			x	x		x	x		x	x		*	*	*		x	*	*	*				
14	C18/08 <i>M. haemolytica</i>			x			x			x	x		x			x	*	*	*	x			x	x		x	x		x	x		*	*	*		x	*	*	*				
15	C19/08 <i>P. multocida</i>			x			x			x	x		x			x	*	*	*	x			x	x		x	x		x	x		*	*	*		x	*	*	*				
16	C21/08 <i>M. haemolytica</i>			x			x			x	x		x			x	*	*	*	x			x	x		x	x		x	x		*	*	*		x	*	*	*				
	C21/08 <i>P. multocida</i>			x			x			x	x		x			x	*	*	*	x			x	x		x	x		x	x		*	*	*		x	*	*	*				
17	C22/08 <i>M. haemolytica</i>			x			x			x	x		x			x	*	*	*	x			x	x		x	x		x	x		*	*	*		x	*	*	*				

A*: Acute pneumonic lung; C**: Chronic pneumonic lung; R: Resistant; I: Intermediate; S: Sensitive; *: not tested; AMP: Ampicillin; AMX: Amoxycillin; CTF: Ceftifour; ENR: Enrofloxacin; ERY: Erythromycin; FLO: Florfenicol; GEN: Gentamycin; MBF: Marbofloxacin; PEN: Penicillin; SXT: Trimethoprim-Sulphamethoxazol; TET: Tetracycline; TIL: Tilmicosin; TUL: Tulathromycin; TYL: Tylosin.

MIC for *M. bovis*

The isolates were found to be resistant to tylosin, tilmicosin, erythromycin, chloramphenicol oxytetracycline and ciprofloxacin with MIC50s of >32 µg/ml, intermediate-

susceptible to florfenicol, spectinomycin, danofloxacin, enrofloxacin and marbofloxacin with MIC50 of 8 µg/ml, and susceptible to lincomycin, clindamycin and tulathromycin with MIC50 of 1, 0.25, 0.25 µg/ml respectively (Table 2).

Table 2. Minimum inhibitory concentrations of *M. bovis* strains (µg/ml).

M. bovis strains	1	2	3	4	5	6	7	8	9	10	11	12	13	14
	TYL	TIL	LCM	CLI	ERY	CHL	FLO	SPT	OTC	DFX	ENR	CIP	TUL	MBF
BC01/08	32	>32	2	0.5	>32	32	8	8	32	8	8	32	1	8
BC02/08	32	>32	1	0.25	>32	32	8	8	32	8	32	32	0.5	>8
BA 03/08	8	>32	0.12	0.12	32	8	8	2	8	0.5	2	2	0.25	0.25
BC04/08	8	>32	0.25	0.12	32	8	8	8	32	8	8	32	0.25	8
BA05/08	8	>32	0.25	0.12	8	8	8	2	32	8	8	32	0.25	8
BC06/08	1	>32	1	8	>32	8	8	8	32	8	8	8	1	8
BA07/08	8	>32	0.12	0.12	>32	8	8	8	8	8	8	32	0.5	2
BA08/08	8	>32	0.25	0.25	0.12	8	8	2	32	8	8	32	0.25	0.25
BC09/08	8	>32	0.12	0.12	8	8	2	2	8	2	8	32	0.25	1
BA10/08	8	>32	0.5	0.12	32	8	8	8	32	8	8	32	0.25	8
BC11/08	32	>32	1	0.25	>32	32	8	8	>32	8	8	32	0.25	8
BA12/08	32	>32	1	0.25	>32	32	8	8	>32	8	8	32	0.25	8
BA14/08	32	>32	2	0.5	>32	32	8	8	>32	8	8	8	0.5	2
BA15/08	32	>32	1	0.25	>32	32	8	8	>32	8	8	32	0.25	8
BC16/08	32	>32	1	0.25	>32	32	8	8	32	1	1	2	0.25	1
BA17/08	8	>32	1	0.12	>32	32	8	8	>32	8	8	32	0.25	8
BA19/08	8	>32	0.5	0.12	>32	32	8	8	>32	8	8	32	0.25	8
BC20/08	>32	>32	>32	>32	>32	8	8	8	>32	>32	32	32	>8	8
BC22/08	32	>32	1	0.25	>32	32	8	8	>32	8	8	32	>8	8
BC23/08	32	>32	2	0.5	>32	32	32	8	32	8	8	32	8	>8
Min	1	>32	0.12	0.12	0.12	8	2	2	8	0.5	1	2	0.25	0.25
Max	>32	>32	>32	>32	>32	32	32	8	>32	>32	32	32	>8	>8
MIC50	32	>32	1	0.25	>32	32	8	8	32	8	8	32	0.25	8

CHL: Chloramphenicol; CIP: Ciprofloxacin; CLI: Clindamycin; DFX: Danofloxacin; ENR: Enrofloxacin; ERY: Erythromycin; FLO: Florfenicol; LCM: Lincomycin; MBF: Marbofloxacin; OTC: Oxytetracycline; SPT: Spectinomycin; TIL: Tilmicosin; TUL: Tulathromycin; TYL: Tylosin.

Guidelines: <2 µg/ml sensitive; >2 to <8 intermediate sensitivity; >8 resistant.

Viral antigen detection

In the test for BVDV antigen, 18% (2 cases) of the acute pneumonic samples 18% (2 cases) of chronic pneumonic samples were found positive. No adenovirus 3, PI, BRSV and BoHV1 antigens were detected in any of the samples.

Molecular typing of *M.bovis*

The results show the existence of two major clusters (Figure 1): the first (A) containing the majority of isolates (85%) and the second (B) containing the remainder (15%). The major cluster could be subdivided into two further groups. No relationship was found between genotypes and whether calves had died of acute or chronic pneumonia. Calves on three farms were infected with both cluster A strains and B strains.




Figure 1. Genetic relationships between *M. bovis* strains based on PFGE profiles using SmaI restriction enzyme.

Discussion

It was previously reported that *M.bovis* and BVDV play an important role in chronic pneumonias in feedlot cattle [17]. In this study, the percentage of BVDV antigen positivity in acute and chronic pneumonic samples were found to be the same. No adenovirus 3, PI, BRSV and BoHV1 antigens were detected in any of the samples. It is clear from this study that *M. bovis* is the major pathogen in this feedlot system being isolated from both acute and chronic lesions of calves dying of respiratory disease. It is probably also widespread throughout the cattle industry in Turkey [5] as it is in many countries worldwide [18].

The results described here confirm those in other studies [6,7] which shows the lack of *in vitro* susceptibility of many antibiotics against *M. bovis* including tylosin, tilmicosin, erythromycin, chloramphenicol and ciprofloxacin and partial susceptibility to florfenicol, spectinomycin, danofloxacin, enrofloxacin and marbofloxacin. Antibiotics which still appear effective *in vitro* comprise lincomycin, clindamycin and tulathromycin. The results presented here are of great concern particularly that evidence of resistance to the fluoroquinolones is being seen which is alarming for human health where these antibiotics are often the last option for treatment of resistant infections [18].

While all isolates of both *M. haemolytica* and *P. multocida* were resistant to gentamicin, some *P. multocida* isolates were resistant to erythromycin and tylosin, trimethoprim-sulphametoxazol and tilmicosin, tulathromycin to enrofloxacin and tetracycline. *M. haemolytica* isolates were largely resistant to erythromycin, tylosin, tetracycline, trimethoprim-sulphametoxazol, but less so to tilmicosin, enrofloxacin, marbofloxacin, florfenicol, ampicillin and penicillin.

When the occurrence and spread of resistance in *Pasteurella*, *Mannheimia* and *M. bovis* organisms is better documented at herd level, this information will help bovine practitioners to minimize the number of therapy failures of bovine pasteurellosis related to antimicrobial resistance.

The results of the molecular typing confirm those of McAuliffe et al. [15] who reported the existence of two markedly distinct groups by several molecular typing tools suggesting two divergent lines of descent that arose during evolution, one from north America and another from Europe. It seems that the European *M. bovis* strains may have mutated from the very closely related *M. agalactiae* which is a pathogen of sheep and goats [15]. It would have been interesting to know the clinical history of the farms where strains of both clusters were detected but these were not recorded. It could be expected that mortality and morbidity may have been higher as mixed strains sometimes give rise to exacerbation of disease [18].

The work reported here indicates that vaccines are urgently needed to combat these infections as antibiotics are clearly failing. However it will be necessary to show that the vaccines are protective against the two major clusters.

References

1. Catry B: *Pasteurella* and *Mannheimia* species from calves: differentiation and antimicrobial resistance. Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium. 2005.
2. Nicholas RA, Ayling RD. *Mycoplasma bovis*: disease, diagnosis and control. *Res Vet Sci.* 2003; 74(2): 105–112.
3. Gagea MI, Bateman KG, Shanahan RA, et al. Naturally occurring *Mycoplasma bovis*-associated pneumonia and polyarthritis in feedlot beef calves. *J Vet Diagn Invest.* 2006; 18(1): 29–40.
4. Özdemir Ü, Erdenliğ S. Dot-immunobinding technique for the identification of *Mycoplasma* species isolated from ruminants. Proceedings of VII National Veterinary Microbiology Congress. Side, Antalya, Turkey. 2006: 119.
5. Sayın Z, Sakmanoğlu A, Uçan US, et al. *Mycoplasma* infections in dairy cattle farms in Turkey. *Turk J Vet Anim Sci.* 2016; 40: 569-574.
6. Ayling RD, Baker SE, Peek ML, Simon AJ, Nicholas RA. Comparison of *in vitro* activity of danofloxacin, florfenicol, oxytetracycline, spectinomycin and tilmicosin against recent field isolates of *Mycoplasma bovis*. *Vet Rec.* 2000; 146(26): 745-747.
7. Barberio A, Flaminio B, De Vlieghe S, et al. Short communication: *In vitro* antimicrobial susceptibility of *Mycoplasma bovis* isolates identified in milk from dairy cattle in Belgium, Germany, and Italy. *J Dairy Sci.* 2016; 99(8): 6578-6584.
8. Nicholas RA, Ayling RD, Stipkovits LP. An experimental vaccine for calf pneumonia caused by *Mycoplasma bovis*: clinical, cultural, serological and pathological findings. *Vaccine.* 2002; 20(29-30): 3569-3575.
9. Nicholas RA, Rosales RS, Loria GR. Mycoplasmaology the big issues. *Anim Husb Dairy Vet Sci.* 2017; 1: 1-4. doi: 10.15761/AHDVS.1000102

10. McAuliffe L, Ellis RJ, Lawes JR, Ayling RD, Nicholas RA. 16S rDNA and denaturing gradient gel electrophoresis; a single generic test for detecting and differentiating *Mycoplasma* species. *J Med Microbiol.* 2005; 54: 731-739.
11. Rosales RS, Churchward CP, Schnee C, et al. Global multilocus sequence typing analysis of *Mycoplasma bovis* isolates reveals two main population clusters. *J Clin Microbiol.* 2015; 53(3): 789-794.
12. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC. *Haemophilus*. In: Koneman EW (ed). *Color Atlas and Textbook of Diagnostic Microbiology*. 4th edition, Lippincott Company. 1992: 288-292.
13. Nicholas RA, Baker S. Recovery of mycoplasma from animals. In: Miles RJ, Nicholas RA (eds). *Mycoplasma Protocols*. Humana Press, Totowa, NJ. 1998: 37-43.
14. Poveda JB, Nicholas RA. Serological identification of mycoplasma by growth inhibition and metabolism inhibition test. In: Miles RJ, Nicholas RAJ (eds). *Mycoplasma Protocols*. Humana Press, Totowa, NJ. 1998: 105-111.
15. McAuliffe L, Kokotovic B, Ayling RD, Nicholas RA. Molecular epidemiological analysis of *Mycoplasma bovis* isolates from the United Kingdom shows two genetically distinct clusters. *J Clin Microbiol.* 2004; 42(10): 4556-4565.
16. Bauer AW, Kirby WM, Sherris JC, Truck M. Antibiotic susceptibility testing by a standardized single method. *Am J Clin Pathol.* 1966; 45: 493-496.
17. Shahriar FM, Clark EG, Janzen E, West K, Wobeser G. Coinfection with bovine viral diarrhoea virus and *Mycoplasma bovis* in feedlot cattle with chronic pneumonia. *Can Vet J.* 2002; 43(11): 863-868.
18. Nicholas RA. Bovine mycoplasmosis: silent and deadly. *Vet Rec.* 2011; 168(17): 459-462.